D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms

PURPOSE: We analyzed the oncogenic potential of RET Δ898-901 mutant and its response to selpercatinib, vandetanib, and cabozantinib in vitro and in a clinical case. MATERIALS AND METHODS: A 35-year-old man with a medullary thyroid cancer (MTC) harboring a somatic D898_E901 RET deletion was sequentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Porcelli, Tommaso, Moccia, Marialuisa, De Stefano, Maria Angela, Ambrosio, Raffaele, Capoluongo, Ettore, Santoro, Massimo, Hadoux, Julien, Schlumberger, Martin, Carlomagno, Francesca, Salvatore, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581602/
https://www.ncbi.nlm.nih.gov/pubmed/37535881
http://dx.doi.org/10.1200/PO.23.00052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581602/
https://www.ncbi.nlm.nih.gov/pubmed/37535881
http://dx.doi.org/10.1200/PO.23.00052

Ejemplares similares